Bullous pemphigoid (BP) is an autoimmune subepidermal blistering disease that predominantly affects elderly individuals and has recently been associated with dipeptidyl peptidase-4 (DPP-4) inhibitor therapy. This evidence concerns the gene DPP4 and bullous pemphigoid.